Experimental feature

Listen to this article

Experimental feature

Healthcare company Fresenius confirmed on Friday evening that it is in talks over a potential acquisition of Akorn, a US-based generic drugmaker

Following an earlier report from Bloomberg about the discussions, the European company said in a statement:

“Fresenius SE & Co KGaA confirms that Fresenius Kabi is currently in discussions with Akorn, Inc., a US specialty generic pharmaceutical company, concerning a potential acquisition of Akorn, Inc. Akorn, Inc. shares are listed on the NASDAQ Global Select Market.

Entry into a formal agreement of a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and the board of directors of Akorn, Inc. There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction. Neither Fresenius SE & Co KGaA nor Akorn, Inc intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reached.”

Akorn shares ended the week 18 per cent higher, amid rumours of the possible deal.

Get alerts on Mergers & Acquisitions when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.

Comments have not been enabled for this article.

Follow the topics in this article